scispace - formally typeset
L

Lluís Puig

Researcher at Autonomous University of Barcelona

Publications -  510
Citations -  16811

Lluís Puig is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Psoriasis & Medicine. The author has an hindex of 56, co-authored 427 publications receiving 13381 citations. Previous affiliations of Lluís Puig include Jikei University School of Medicine & Pompeu Fabra University.

Papers
More filters
Journal ArticleDOI

Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients.

A T Vila, +5 more
- 01 Aug 2005 - 
TL;DR: Anakinra, a recombinant human form of interleukin‐1 receptor antagonist, is used to treat patients with active rheumatoid arthritis.
Journal ArticleDOI

Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre.

A. López-Ferrer, +3 more
- 01 Nov 2013 - 
TL;DR: Patients with moderate‐to‐severe psoriasis treated with adalimumab in daily clinical practice are different from those in clinical trials, and outcomes may differ in different geographical settings.
Journal ArticleDOI

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

Giampiero Girolomoni, +11 more
- 05 Jun 2015 - 
TL;DR: It is hypothesize that a patient-centered therapeutic approach, undertaken early in the psoriasis treatment pathway (“early intervention”) with the goal of complete clearance, may improve control of cutaneous symptoms and may also modify disease course and burden.
Journal ArticleDOI

Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema.

A. Alomar, +3 more
- 01 Oct 2003 - 
TL;DR: There was a significant decrease in visual scores with time from day 2 to day 7, and the corresponding mean decreases in scores were 0.73 and 1.04, respectively, in favour of tacrolimus.
Journal ArticleDOI

Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study

Craig L. Leonardi, +10 more
- 01 Nov 2018 - 
TL;DR: IXE sustained high responses with clearance of skin and nail lesions, with no new safety concerns through 3 years, and was approved as an approved therapy for patients with moderate‐to‐severe plaque psoriasis.